JP2018516586A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516586A5
JP2018516586A5 JP2017564369A JP2017564369A JP2018516586A5 JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5 JP 2017564369 A JP2017564369 A JP 2017564369A JP 2017564369 A JP2017564369 A JP 2017564369A JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5
Authority
JP
Japan
Prior art keywords
interleukin
growth factor
activity
nanograms
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564369A
Other languages
English (en)
Japanese (ja)
Other versions
JP6799895B2 (ja
JP2018516586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063077 external-priority patent/WO2016198480A1/en
Publication of JP2018516586A publication Critical patent/JP2018516586A/ja
Publication of JP2018516586A5 publication Critical patent/JP2018516586A5/ja
Application granted granted Critical
Publication of JP6799895B2 publication Critical patent/JP6799895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564369A 2015-06-09 2016-06-08 ＴＣＲγδ＋Ｔ細胞の生産方法 Active JP6799895B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PT2015047568 2015-06-09
PT20151000047568 2015-06-09
PT2016032002 2016-05-12
PT20161000032002 2016-05-12
PCT/EP2016/063077 WO2016198480A1 (en) 2015-06-09 2016-06-08 Methods for the production of tcr gamma delta+ t cells

Publications (3)

Publication Number Publication Date
JP2018516586A JP2018516586A (ja) 2018-06-28
JP2018516586A5 true JP2018516586A5 (enExample) 2019-07-11
JP6799895B2 JP6799895B2 (ja) 2020-12-16

Family

ID=56132913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564369A Active JP6799895B2 (ja) 2015-06-09 2016-06-08 ＴＣＲγδ＋Ｔ細胞の生産方法

Country Status (9)

Country Link
US (2) US11166983B2 (enExample)
EP (2) EP3307875B1 (enExample)
JP (1) JP6799895B2 (enExample)
CN (2) CN114958738A (enExample)
AU (3) AU2016274633B2 (enExample)
CA (1) CA2988050A1 (enExample)
EA (1) EA201890013A1 (enExample)
WO (1) WO2016198480A1 (enExample)
ZA (1) ZA201800121B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
KR20240063197A (ko) 2015-06-09 2024-05-09 감마델타 테라퓨틱스 엘티디 Tcr 감마 델타 양성 t 세포의 생산 방법
CN108473958A (zh) * 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
CA3082818A1 (en) * 2017-11-15 2019-05-23 Adicet Bio Inc. Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
BR112021006182A2 (pt) 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
US12698340B2 (en) 2018-10-01 2026-08-04 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
US20220088074A1 (en) * 2019-02-21 2022-03-24 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
CA3143198A1 (en) * 2019-06-14 2020-12-17 G Tech Bio Llc Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
CA3148588A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
WO2021186137A1 (en) 2020-03-20 2021-09-23 GammaDelta Therapeutics Limited V delta1+ t cells for the treatment of myeloid malignancies
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
CN113913384A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 一种制备靶点特异性nk细胞的方法及其应用
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
US20230302132A1 (en) * 2020-08-14 2023-09-28 Shanghai Xinghua Bio Pharmaceutical Science & Technology Co., Ltd Method for preparing universal immune cells and use thereof
CA3202233A1 (en) * 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
CA3250985A1 (en) 2022-02-16 2023-08-24 Priothera Sas CAR CELL TREATMENT METHODS IN COMBINATION WITH S1P RECEIVER MODULATORS
PE20242341A1 (es) 2022-04-04 2024-12-12 Gammadelta Therapeutics Ltd Blindaje genetico novedoso
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
US11750950B1 (en) * 2022-05-26 2023-09-05 Omnivision Technologies, Inc. Voltage domain global shutter readout circuit timing
CN115678846B (zh) * 2022-09-01 2023-06-16 广东龄值生物科技有限公司 一种肿瘤特异性γδT细胞及其制备方法
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2026013616A1 (en) * 2024-07-10 2026-01-15 Takeda Pharmaceutical Company Limited Compositions and methods for treating cancer
WO2026033421A1 (en) 2024-08-05 2026-02-12 Takeda Pharmaceutical Company Limited IDENTIFICATION OF SUITABLE DONORS OF γδ T CELLS
WO2026088163A1 (en) 2024-10-25 2026-04-30 Takeda Pharmaceutical Company Limited Compositions of engineered cytokine expressing cells and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511760A (en) * 1998-11-04 2003-10-31 Hemosol Inc Methods for the production of TcR gamma delta T cells
ES2336302T3 (es) * 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
US20030157060A1 (en) 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
ATE476497T1 (de) * 2004-08-19 2010-08-15 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
CA2629532C (en) * 2005-11-18 2016-08-09 University Health Network Method of expanding double negative t cells
JPWO2008111430A1 (ja) * 2007-03-09 2010-06-24 タカラバイオ株式会社 γδＴ細胞集団の製造方法
RS55730B1 (sr) 2010-10-21 2017-07-31 Syngenta Ltd Agrohemijski koncentrati koji sadrže alkoksilovane dodatke
EP2710123B1 (en) * 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
CN106399245A (zh) * 2016-11-30 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种γδT细胞的培养方法

Similar Documents

Publication Publication Date Title
Karachi et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
Kaur et al. Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs
Kratchmarov et al. TCF1 expression marks self-renewing human CD8+ T cells
Yan et al. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yang et al. Phase I study of random healthy donor–derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors
Seifert et al. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors
Icheva et al. Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation
Orange et al. Coley’s lessons remembered: augmenting mistletoe therapy
Fridlender et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms
Lang et al. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma
CN106659742B (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
Wang et al. Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
WO2012156958A4 (en) Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
Sköld et al. Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
WO2021062221A1 (en) Compositions comprising regulatory t cells and methods of making and using the same
US20230066340A1 (en) Populations of enriched regulatory t cells and methods for producing same
JP2026000910A (ja) 免疫回避腫瘍の処置
Malfitano et al. Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer
Tuthill et al. Thymosin α1 continues to show promise as an enhancer for vaccine response
Song et al. Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma
Liu et al. IL-2/GM-CSF enhances CXCR3 expression in car-T cells via the PI3K/akt and ERK1/2 pathways
CN106103701A (zh) 改造的自然杀手细胞及其组成与用途
Bialek-Waldmann et al. Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre-or post-stem cell transplantation
Li et al. Dendritic cells therapy with cytokine-induced killer cells and activated cytotoxic T cells attenuated Th2 bias immune response
CN109136182A (zh) 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用